Clinical trial
Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a…
NCT00042094 · DynPort Vaccine Company LLC, A GDIT Company, Industry · Completed
Key facts
| NCT number | NCT00042094 |
|---|---|
| Title | Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® |
| Official title | A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®) |
| Lead sponsor | DynPort Vaccine Company LLC, A GDIT Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Smallpox |
| Intervention type | Biological |
| Interventions | Cell-Cultured Smallpox Vaccine compared to Dryvax® |
| Enrollment | 350 |
| Start date | Mar 1, 2002 |
| Completion | Mar 1, 2003 |
| First posted | Jul 26, 2002 |
| Last update posted | Jun 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: